Innate Pharma's earnings have been declining at an average annual rate of -18.6%, while the Biotechs industry saw earnings growing at 17% annually. Revenues have been declining at an average rate of 23% per year.
Key information
-18.60%
Earnings growth rate
-17.00%
EPS growth rate
Biotechs Industry Growth
-14.59%
Revenue growth rate
-22.98%
Return on equity
n/a
Net Margin
-546.11%
Next Earnings Update
17 Sep 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Innate Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
XTRA:IDD Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
9
-49
19
0
30 Sep 25
11
-48
20
0
30 Jun 25
13
-46
20
0
31 Mar 25
16
-48
20
0
31 Dec 24
20
-49
20
0
30 Sep 24
27
-42
19
0
30 Jun 24
34
-34
19
0
31 Mar 24
48
-21
19
0
31 Dec 23
62
-8
18
0
30 Sep 23
57
-35
19
0
30 Jun 23
52
-63
19
0
31 Mar 23
55
-60
21
0
31 Dec 22
58
-58
22
0
30 Sep 22
57
-40
24
0
30 Jun 22
57
-22
25
0
31 Mar 22
41
-34
25
0
31 Dec 21
25
-45
26
0
30 Jun 21
46
-8
17
0
31 Mar 21
58
-4
18
0
31 Dec 20
70
-1
19
0
30 Sep 20
67
-54
31
0
30 Jun 20
63
-44
31
0
31 Mar 20
75
-33
28
0
31 Dec 19
85
8
21
0
30 Sep 19
108
5
24
0
30 Jun 19
130
31
22
0
31 Mar 19
112
17
20
0
31 Dec 18
94
3
18
0
30 Sep 18
70
-19
16
0
30 Jun 18
46
-40
15
0
31 Mar 18
45
-44
16
0
31 Dec 17
44
-48
17
0
30 Sep 17
55
-28
16
0
30 Jun 17
66
-8
14
0
31 Mar 17
66
3
12
0
31 Dec 16
66
13
10
0
30 Sep 16
53
5
8
0
30 Jun 16
41
-2
7
0
31 Mar 16
33
-4
6
0
31 Dec 15
25
-7
6
0
30 Sep 15
17
-13
5
0
30 Jun 15
8
-19
4
0
Quality Earnings: IDD is currently unprofitable.
Growing Profit Margin: IDD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDD is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare IDD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.2%).
Return on Equity
High ROE: IDD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/01 01:35
End of Day Share Price
2026/05/27 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.